Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

1/30/24 7:07:59 AM ET

$BBIO

$NVTA

Biotechnology: Pharmaceutical Preparations

Health Care

Medical Specialities

Health Care

Get the next $BBIO alert in real time by email

Invitae (NYSE:NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, designed to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs.

Get the next $BBIO alert in real time by email

Crush Q3 2025 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$BBIO
$NVTA

Company	Date	Price Target	Rating	Analyst
BridgeBio Pharma Inc. $BBIO	7/30/2025	$56.00	Outperform	Raymond James
BridgeBio Pharma Inc. $BBIO	7/21/2025	$66.00	Buy	Truist
BridgeBio Pharma Inc. $BBIO	7/14/2025	$70.00	Buy	Jefferies
BridgeBio Pharma Inc. $BBIO	7/9/2025	$60.00	Perform → Outperform	Oppenheimer
BridgeBio Pharma Inc. $BBIO	6/17/2025	$49.00	Outperform	Wolfe Research
BridgeBio Pharma Inc. $BBIO	3/31/2025	$50.00	Buy	Redburn Atlantic
BridgeBio Pharma Inc. $BBIO	10/16/2024		Sector Outperform	Scotiabank
BridgeBio Pharma Inc. $BBIO	10/3/2024		Perform	Oppenheimer

More analyst ratings

Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$BBIO
$NVTA

Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$BBIO
$NVTA

$BBIO
$NVTA
FDA approvals

FDA Approval for ATTRUBY issued to BRIDGEBIO PHARMA INC

$BBIO
$NVTA
Analyst Ratings

Raymond James resumed coverage on BridgeBio Pharma with a new price target

Truist initiated coverage on BridgeBio Pharma with a new price target

Jefferies initiated coverage on BridgeBio Pharma with a new price target

$BBIO
$NVTA
SEC Filings

SEC Form 144 filed by BridgeBio Pharma Inc.

SEC Form 144 filed by BridgeBio Pharma Inc.

SEC Form 144 filed by BridgeBio Pharma Inc.

$BBIO
$NVTA
Press Releases

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM

BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025

$BBIO
$NVTA
Insider Purchases

Amendment: Director Valantine Hannah bought $24,948 worth of shares (1,752 units at $14.24), increasing direct ownership by 114% to 3,294 units (SEC Form 4)

Amendment: Director Valantine Hannah bought $30,028 worth of shares (2,338 units at $12.84) (SEC Form 4)

Valantine Hannah bought $44,476 worth of shares (3,433 units at $12.96) (SEC Form 4)

$BBIO
$NVTA
Insider Trading

Chief Executive Officer Kumar Neil sold $4,383,442 worth of shares (80,000 units at $54.79) (SEC Form 4)

Director Mccormick Frank sold $3,933,544 worth of shares (74,000 units at $53.16) and exercised 74,000 shares at a strike of $11.92 (SEC Form 4)

Chief Executive Officer Kumar Neil sold $4,175,835 worth of shares (80,000 units at $52.20) (SEC Form 4)

$BBIO
$NVTA
Leadership Updates

BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline

Aranscia Acquires YouScript from Invitae

$BBIO
$NVTA
Financials

BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

$BBIO
$NVTA
Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $BBIO$NVTA

Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $BBIO$NVTA

$BBIO$NVTA FDA approvals

FDA Approval for ATTRUBY issued to BRIDGEBIO PHARMA INC

$BBIO$NVTA Analyst Ratings

Raymond James resumed coverage on BridgeBio Pharma with a new price target

Truist initiated coverage on BridgeBio Pharma with a new price target

Jefferies initiated coverage on BridgeBio Pharma with a new price target

$BBIO$NVTA SEC Filings

SEC Form 144 filed by BridgeBio Pharma Inc.

SEC Form 144 filed by BridgeBio Pharma Inc.

SEC Form 144 filed by BridgeBio Pharma Inc.

$BBIO$NVTA Press Releases

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM

BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025

$BBIO$NVTA Insider Purchases

Amendment: Director Valantine Hannah bought $24,948 worth of shares (1,752 units at $14.24), increasing direct ownership by 114% to 3,294 units (SEC Form 4)

Amendment: Director Valantine Hannah bought $30,028 worth of shares (2,338 units at $12.84) (SEC Form 4)

Valantine Hannah bought $44,476 worth of shares (3,433 units at $12.96) (SEC Form 4)

$BBIO$NVTA Insider Trading

Chief Executive Officer Kumar Neil sold $4,383,442 worth of shares (80,000 units at $54.79) (SEC Form 4)

Director Mccormick Frank sold $3,933,544 worth of shares (74,000 units at $53.16) and exercised 74,000 shares at a strike of $11.92 (SEC Form 4)

Chief Executive Officer Kumar Neil sold $4,175,835 worth of shares (80,000 units at $52.20) (SEC Form 4)

$BBIO$NVTA Leadership Updates

BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline

Aranscia Acquires YouScript from Invitae

$BBIO$NVTA Financials

BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

$BBIO$NVTA Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

Recent Analyst Ratings for
$BBIO
$NVTA

Recent Analyst Ratings for
$BBIO
$NVTA

$BBIO
$NVTA
FDA approvals

$BBIO
$NVTA
Analyst Ratings

$BBIO
$NVTA
SEC Filings

$BBIO
$NVTA
Press Releases

$BBIO
$NVTA
Insider Purchases

$BBIO
$NVTA
Insider Trading

$BBIO
$NVTA
Leadership Updates

$BBIO
$NVTA
Financials

$BBIO
$NVTA
Large Ownership Changes